Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SALMETEROL XINAFOATE & FLUTICASONE PROPIONATE

Form:

11 of 11 products shown

All strengths: Limited Use — Reason for Use code 330 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 330 required
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (R03A, R03AK) — coverage varies; not interchangeable

  • Budesonide + formoterol (Symbicort 100 Turbuhaler): limited Use 330
  • Fluticasone furoate + vilanterol (Breo Ellipta): limited Use 330, Limited Use 330, 456
  • Formoterol + mometasone furoate (Zenhale): limited Use 330
  • Salbutamol (Teva-Salbutamol Sterinebs P.F.): general benefit, Limited Use 256, 257, 258, 259, Limited Use 265, 266, 267, 268, Not a benefit
  • Terbutaline (Bricanyl Turbuhaler): general benefit
  • Aclidinium + formoterol (Duaklir Genuair): limited Use 459

8 more in the class list below

Advair 125 · DIN 02245126 · 25/125mcg/Metered Dose · inhaler, 120 doses

Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Advair 125 · DIN 02245126 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2003-01-30 Health Canada: Marketed since 2001-12-21 · brand ADVAIR · ATC R03AK06 SALMETEROL AND FLUTICASONE, R03AK06 SALMETEROL AND FLUTICASONE, R03AK06 SALMETEROL AND FLUTICASONE · form Aerosol (metered-dose) · route Inhalation · ingredients SALMETEROL (SALMETEROL XINAFOATE) 25 MCG/ACT, FLUTICASONE PROPIONATE 125 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Advair 125: Formulary list price $138.4500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $138.4500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69136 · Verify on the e-Formulary ↗ (DIN 02245126)

Source record
DIN 02245126: Advair 125 Raw flags: sec12=Y, sec3=Y Item: 121200085; group id 237; item number 0419; lccId 00044; manufacturer id GSK Source form: Inh-120 Dose Pk; strength: 25/125mcg/Metered Dose Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $138.4500; ministry $138.4500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245126 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69136
Shortage status: resolved shortage (ended 2024-07-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245126
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Advair 250 · DIN 02245127 · 25/250mcg/Metered Dose · inhaler, 120 doses

Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Advair 250 · DIN 02245127 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2003-01-30 Health Canada: Marketed since 2001-12-21 · brand ADVAIR · ATC R03AK06 SALMETEROL AND FLUTICASONE, R03AK06 SALMETEROL AND FLUTICASONE · form Aerosol (metered-dose) · route Inhalation · ingredients FLUTICASONE PROPIONATE 250 MCG/ACT, SALMETEROL (SALMETEROL XINAFOATE) 25 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Advair 250: Formulary list price $196.5400/unit (unit not stated in source; not the patient's cost)

Ministry pays: $196.5400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69137 · Verify on the e-Formulary ↗ (DIN 02245127)

Source record
DIN 02245127: Advair 250 Raw flags: sec12=Y, sec3=Y Item: 121200086; group id 237; item number 0420; lccId 00044; manufacturer id GSK Source form: Inh-120 Dose Pk; strength: 25/250mcg/Metered Dose Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $196.5400; ministry $196.5400 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245127 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69137
Shortage status: resolved shortage (ended 2025-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245127
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Advair Diskus · DIN 02240835 · 50/100mcg · inhaler, 60 doses

Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Advair Diskus (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Advair Diskus · DIN 02240835 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2001-10-11 Health Canada: Marketed since 2002-03-12 · brand ADVAIR 100 DISKUS · ATC R03AK06 SALMETEROL AND FLUTICASONE · form Powder · route Inhalation · ingredients SALMETEROL (SALMETEROL XINAFOATE) 50 MCG/ACT, FLUTICASONE PROPIONATE 100 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $42.4050 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64426 · Verify on the e-Formulary ↗ (DIN 02240835)

Source record
DIN 02240835: Advair Diskus Raw flags: sec12=Y, sec3=Y Item: 121200083; group id 237; item number 0421; lccId 00044; manufacturer id GSK Source form: Inh-60 Dose Pk; strength: 50/100mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $115.6500; ministry $42.4050 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240835 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64426
Interchangeable products
PMS-FluticasonePropionateSalmeterol DPI · DIN 02494507 · $42.4050 Wixela Inhub · DIN 02495597 · $42.4050
Shortage status: resolved shortage (ended 2024-11-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240835
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Advair Diskus · DIN 02240836 · 50/250mcg · inhaler, 60 doses

Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Advair Diskus (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Advair Diskus · DIN 02240836 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-07-17 Health Canada: Marketed since 2002-04-03 · brand ADVAIR 250 DISKUS · ATC R03AK06 SALMETEROL AND FLUTICASONE · form Powder · route Inhalation · ingredients FLUTICASONE PROPIONATE 250 MCG/ACT, SALMETEROL (SALMETEROL XINAFOATE) 50 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $50.7600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64427 · Verify on the e-Formulary ↗ (DIN 02240836)

Source record
DIN 02240836: Advair Diskus Raw flags: sec12=Y, sec3=Y Item: 121200080; group id 237; item number 0422; lccId 00044; manufacturer id GSK Source form: Inh-60 Dose Pk; strength: 50/250mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $138.4500; ministry $50.7600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240836 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64427
Interchangeable products
PMS-FluticasonePropionateSalmeterol DPI · DIN 02494515 · $50.7600 Wixela Inhub · DIN 02495600 · $50.7600
Shortage status: resolved shortage (ended 2025-05-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240836
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Advair Diskus · DIN 02240837 · 50/500mcg · inhaler, 60 doses

Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Advair Diskus (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Advair Diskus · DIN 02240837 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-07-17 Health Canada: Marketed since 2002-03-08 · brand ADVAIR 500 DISKUS · ATC R03AK06 SALMETEROL AND FLUTICASONE · form Powder · route Inhalation · ingredients FLUTICASONE PROPIONATE 500 MCG/ACT, SALMETEROL (SALMETEROL XINAFOATE) 50 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $72.0600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64428 · Verify on the e-Formulary ↗ (DIN 02240837)

Source record
DIN 02240837: Advair Diskus Raw flags: sec12=Y, sec3=Y Item: 121200081; group id 237; item number 0423; lccId 00044; manufacturer id GSK Source form: Inh-60 Dose Pk; strength: 50/500mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $196.5400; ministry $72.0600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240837 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64428
Interchangeable products
PMS-FluticasonePropionateSalmeterol DPI · DIN 02494523 · $72.0600 Wixela Inhub · DIN 02495619 · $72.0600
Shortage status: resolved shortage (ended 2023-04-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240837
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-FluticasonePropionateSalmeterol DPI · DIN 02494507 · 50/100mcg · inhaler, 60 doses

Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-FluticasonePropionateSalmeterol DPI · DIN 02494507 Manufacturer: Pharmascience Inc.; listing date 2020-04-30 Health Canada: Marketed since 2020-03-05 · brand PMS-FLUTICASONE PROPIONATE/SALMETEROL DPI · ATC R03AK06 SALMETEROL AND FLUTICASONE, R03AK06 SALMETEROL AND FLUTICASONE · form Powder · route Inhalation · ingredients SALMETEROL (SALMETEROL XINAFOATE) 50 MCG/ACT, FLUTICASONE PROPIONATE 100 MCG/ACT · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-FluticasonePropionateSalmeterol DPI: Formulary list price $42.4050/unit (unit not stated in source; not the patient's cost)

Ministry pays: $42.4050 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98451 · Verify on the e-Formulary ↗ (DIN 02494507)

Source record
DIN 02494507: PMS-FluticasonePropionateSalmeterol DPI Raw flags: sec12=Y, sec3=Y Item: 121200083; group id 237; item number 0421; lccId 00044; manufacturer id PMS Source form: Inh-60 Dose Pk; strength: 50/100mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $42.4050; ministry $42.4050 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02494507 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98451
Interchangeable products
Advair Diskus · DIN 02240835 · $42.4050 Wixela Inhub · DIN 02495597 · $42.4050
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02494507
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-FluticasonePropionateSalmeterol DPI · DIN 02494515 · 50/250mcg · inhaler, 60 doses

Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-FluticasonePropionateSalmeterol DPI · DIN 02494515 Manufacturer: Pharmascience Inc.; listing date 2020-04-30 Health Canada: Marketed since 2020-03-05 · brand PMS-FLUTICASONE PROPIONATE/SALMETEROL DPI · ATC R03AK06 SALMETEROL AND FLUTICASONE, R03AK06 SALMETEROL AND FLUTICASONE · form Powder · route Inhalation · ingredients SALMETEROL (SALMETEROL XINAFOATE) 50 MCG/ACT, FLUTICASONE PROPIONATE 250 MCG/ACT · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-FluticasonePropionateSalmeterol DPI: Formulary list price $50.7600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $50.7600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98452 · Verify on the e-Formulary ↗ (DIN 02494515)

Source record
DIN 02494515: PMS-FluticasonePropionateSalmeterol DPI Raw flags: sec12=Y, sec3=Y Item: 121200080; group id 237; item number 0422; lccId 00044; manufacturer id PMS Source form: Inh-60 Dose Pk; strength: 50/250mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $50.7600; ministry $50.7600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02494515 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98452
Interchangeable products
Advair Diskus · DIN 02240836 · $50.7600 Wixela Inhub · DIN 02495600 · $50.7600
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02494515
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-FluticasonePropionateSalmeterol DPI · DIN 02494523 · 50/500mcg · inhaler, 60 doses

Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-FluticasonePropionateSalmeterol DPI · DIN 02494523 Manufacturer: Pharmascience Inc.; listing date 2020-04-30 Health Canada: Marketed since 2020-03-05 · brand PMS-FLUTICASONE PROPIONATE/SALMETEROL DPI · ATC R03AK06 SALMETEROL AND FLUTICASONE, R03AK06 SALMETEROL AND FLUTICASONE · form Powder · route Inhalation · ingredients SALMETEROL (SALMETEROL XINAFOATE) 50 MCG/ACT, FLUTICASONE PROPIONATE 500 MCG/ACT · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-FluticasonePropionateSalmeterol DPI: Formulary list price $72.0600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $72.0600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98453 · Verify on the e-Formulary ↗ (DIN 02494523)

Source record
DIN 02494523: PMS-FluticasonePropionateSalmeterol DPI Raw flags: sec12=Y, sec3=Y Item: 121200081; group id 237; item number 0423; lccId 00044; manufacturer id PMS Source form: Inh-60 Dose Pk; strength: 50/500mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $72.0600; ministry $72.0600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02494523 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98453
Interchangeable products
Advair Diskus · DIN 02240837 · $72.0600 Wixela Inhub · DIN 02495619 · $72.0600
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02494523
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Wixela Inhub · DIN 02495597 · 50/100mcg · inhaler, 60 doses

Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Wixela Inhub · DIN 02495597 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2020-04-30 Health Canada: Marketed since 2020-02-13 · brand WIXELA INHUB · ATC R03AK06 SALMETEROL AND FLUTICASONE, R03AK06 SALMETEROL AND FLUTICASONE · form Powder · route Inhalation · ingredients FLUTICASONE PROPIONATE 100 MCG/ACT, SALMETEROL (SALMETEROL XINAFOATE) 50 MCG/ACT · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Wixela Inhub: Formulary list price $42.4050/unit (unit not stated in source; not the patient's cost)

Ministry pays: $42.4050 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98549 · Verify on the e-Formulary ↗ (DIN 02495597)

Source record
DIN 02495597: Wixela Inhub Raw flags: sec12=Y, sec3=Y Item: 121200083; group id 237; item number 0421; lccId 00044; manufacturer id MYL Source form: Inh-60 Dose Pk; strength: 50/100mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $42.4050; ministry $42.4050 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495597 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98549
Interchangeable products
Advair Diskus · DIN 02240835 · $42.4050 PMS-FluticasonePropionateSalmeterol DPI · DIN 02494507 · $42.4050
Shortage status: resolved shortage (ended 2025-01-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02495597
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Wixela Inhub · DIN 02495600 · 50/250mcg · inhaler, 60 doses

Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Wixela Inhub · DIN 02495600 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2020-03-31 Health Canada: Marketed since 2020-02-13 · brand WIXELA INHUB · ATC R03AK06 SALMETEROL AND FLUTICASONE, R03AK06 SALMETEROL AND FLUTICASONE · form Powder · route Inhalation · ingredients SALMETEROL (SALMETEROL XINAFOATE) 50 MCG/ACT, FLUTICASONE PROPIONATE 250 MCG/ACT · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Wixela Inhub: Formulary list price $50.7600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $50.7600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98550 · Verify on the e-Formulary ↗ (DIN 02495600)

Source record
DIN 02495600: Wixela Inhub Raw flags: sec12=Y, sec3=Y Item: 121200080; group id 237; item number 0422; lccId 00044; manufacturer id MYL Source form: Inh-60 Dose Pk; strength: 50/250mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $50.7600; ministry $50.7600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495600 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98550
Interchangeable products
Advair Diskus · DIN 02240836 · $50.7600 PMS-FluticasonePropionateSalmeterol DPI · DIN 02494515 · $50.7600
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02495600
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Wixela Inhub · DIN 02495619 · 50/500mcg · inhaler, 60 doses

Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
Write on scriptLU code 330 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Wixela Inhub · DIN 02495619 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2020-03-31 Health Canada: Marketed since 2020-02-13 · brand WIXELA INHUB · ATC R03AK06 SALMETEROL AND FLUTICASONE, R03AK06 SALMETEROL AND FLUTICASONE · form Powder · route Inhalation · ingredients SALMETEROL (SALMETEROL XINAFOATE) 50 MCG/ACT, FLUTICASONE PROPIONATE 500 MCG/ACT · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Wixela Inhub: Formulary list price $72.0600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $72.0600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98551 · Verify on the e-Formulary ↗ (DIN 02495619)

Source record
DIN 02495619: Wixela Inhub Raw flags: sec12=Y, sec3=Y Item: 121200081; group id 237; item number 0423; lccId 00044; manufacturer id MYL Source form: Inh-60 Dose Pk; strength: 50/500mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $72.0600; ministry $72.0600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495619 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98551
Interchangeable products
Advair Diskus · DIN 02240837 · $72.0600 PMS-FluticasonePropionateSalmeterol DPI · DIN 02494523 · $72.0600
Shortage status: resolved shortage (ended 2026-08-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02495619
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (12:12 Sympathomimetic (Adrenergic) Agents) and how they are covered

Matched class: 12:12 Sympathomimetic (Adrenergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE, SALBUTAMOL 12:12 Sympathomimetic (Adrenergic) Agents

BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg/6mcg, 200mcg/6mcg · Pd Inh-120 Dose Pk

FLUTICASONE FUROATE & VILANTEROL

· 2 products · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) · strengths: 100mcg & 25mcg, 200mcg & 25mcg · Blister Pd Inh-30 Dose Pk

MOMETASONE FUROATE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg & 5mcg, 200mcg & 5mcg · Metered Dose Inh-120 Dose Pk

SALBUTAMOL

· 20 products · Limited Use, codes 265, 266, 267, 268 (4), Listed, not a benefit (8), Limited Use, codes 256, 257, 258, 259 (1), General benefit (7) · strengths: 1mg/mL, 2mg/mL, 5mg/mL, 100mcg/Metered Dose, 2mg, 4mg · Inh Sol- 2.5mL Pk, Inh Sol-10mL Pk, Inh-200 dose Pk, Tab

TERBUTALINE SULFATE

· 2 products · General benefit · strengths: 0.5mg/Dose · Inh-100 Dose Pk, Inh-120 Dose Pk

ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 459 · strengths: 400mcg & 12mcg · Metered Dose Pd Inh-60 Dose Pk

BUDESONIDE&GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE)&FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 638 · strengths: 160mcg & 7.2mcg & 5mcg/Act · Metered Dose Inh-120 Dose Pk

FLUTICASONE FUROATE & UMECLIDINIUM BROMIDE & VILANTEROL TRIFENATATE

· 1 products · Limited Use, codes 567 · strengths: 100mcg & 62.5mcg & 25mcg · Pd Inh-30 Dose Pk

FORMOTEROL FUMARATE

· 1 products · Limited Use, codes 132 · strengths: 12mcg/Cap · Inh Pd-Device Pk

FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 132 · strengths: 6mcg/Metered Dose, 12mcg/Metered Dose · Pd Inh-60 Dose Pk

INDACATEROL

· 1 products · Limited Use, codes 443 · strengths: 75mcg · Inh Pd-Cap

INDACATEROL & GLYCOPYRRONIUM

· 1 products · Limited Use, codes 459 · strengths: 110mcg & 50mcg · Inh Pd-Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:12 and 4 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: copd
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. FLUTICASONE FUROATE & VILANTEROL · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) BREO ELLIPTA 100/25 mcg once daily is the only strength indicated for the treatment of COPD. PM: https://pdf.hres.ca/dpd_pm/00049111.PDF; date January 7, 2019; DIN 02408872; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Asthma ADVAIR/ADVAIR DISKUS (fluticasone propionate/salmeterol) is a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) indicated for the maintenance treatment of asthma, in patients with reversible obstructive airways disease. ADVAIR/ADVAIR DISKUS should be prescribed for patients not adequately controlled on a long-term asthma control medication, such as an ICS, or whose disease severity clearly warrants treatment with both an ICS and a LABA. ADVAIR/ADVAIR DISKUS is not indicated for patients whose asthma can be managed by occasional use of a rapid onset, short duration, inhaled beta2-agonist, or for patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of a rapid onset, short duration, inhaled beta2-agonist. Page 3 of 70 ADVAIR/ADVAIR DISKUS should not be used as a rescue medication. To relieve acute asthmatic symptoms, a rapid onset, short duration inhaled bronchodilator (e.g. salbutamol) should be used. Chronic Obstructive Pulmonary Disease (COPD) ADVAIR DISKUS 250 a… https://pdf.hres.ca/dpd_pm/00056976.PDF PM date: June 17, 2020 Source product: ADVAIR 100 DISKUS; DIN 02240835; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.